Overview

Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas

Status:
Active, not recruiting
Trial end date:
2023-05-31
Target enrollment:
Participant gender:
Summary
This is a pilot study of pembrolizumab-based therapy in previously treated extrapulmonary poorly differentiated neuroendocrine carcinoma
Phase:
Phase 2
Details
Lead Sponsor:
University of California, San Francisco
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Albumin-Bound Paclitaxel
Irinotecan
Paclitaxel
Pembrolizumab